Versartis to Present at the Canaccord Genuity Growth Conference

MENLO PARK, Calif., Aug. 02, 2017 -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced that Jay Shepard, President and CEO, is scheduled to present at the Canaccord Genuity 37^th Annual Growth Conference on Wednesday, August 9, 2017 at the InterContinental Boston.

Event: Canaccord Genuity 37^th Annual Growth Conference
Date: Wednesday, August 9, 2017
Time: 10:30 a.m. ET / 7:30 a.m. PT
Location: InterContinental Boston – Boston, MA

An audio webcast of the Company's presentation will be available on the investor relations section of the Versartis website at www.versartis.com. A replay of the presentation will be available for 90 days.

About Versartis, Inc.

Versartis, Inc. is an endocrine-focused biopharmaceutical company initially developing somavaratan, a novel, long-acting form of recombinant human growth hormone in late-stage clinical trials for the treatment of GHD in children and adults. Somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving adherence and, therefore, treatment outcomes.

For more information on Versartis, visit www.versartis.com.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, plans and timing of our clinical trials and the potential for eventual regulatory approval of somavaratan. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. We discuss many of these risks in greater detail under the heading "Risk Factors" contained in our Annual Report on Form 10-K for the year ended December 31, 2016 and in our Quarterly Report on Form 10-Q for the three months ended March 31, 2017 which are on file with the Securities and Exchange Commission (SEC). Forward-looking statements are not guarantees of future performance, and our actual results may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release and we assume no obligation to update them after the date of this press release.

Contacts:

Corporate Communications: 
Christine Labaree
Corporate Affairs
(650) 600-1697
[email protected]

Investors:
David Burke
Director, Investor Relations
(650) 516-2703 
[email protected]